FumitoItoMDPhD, FACS

Breast, Melanoma, Surgical Oncology (Other than Breast)

Surgical Oncologist, University of Southern California, Co-Leader of the Translational and Clinical Sciences Research (TACS) Program and Director of the Flow Cytometry and Immune Monitoring Core, Norris Comprehensive Cancer Center

Join to view full profile

Dr. Ito is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ito's full profile

Already have an account?

Office
1450 San Pablo St
Ste 6200
Los Angeles, CA 90033
Phone+1 323-442-9062

Clinical Expertise

Breast cancer, Breast surgery, Tumor immunotherapy, Sarcomas, Melanoma and cutaneous malignancies, Cancer Vaccines

Education & Training

Strong Memorial Hospital of the University of RochesterFellowship, Complex General Surgical Oncology, 2008 - 2010
University of Wisconsin Hospitals and ClinicsResidency, Surgery, 2005 - 2008
University of WashingtonResidency, Surgery, 2003 - 2005
Shiga University of Medical ScienceClass of 1995

Certifications & Licensure

CA State Medical License 2021 - 2025
NY State Medical License 2008 - 2025
MI State Medical License 2010 - 2017
WI State Medical License 2007 - 2011
American Board of Surgery Surgery

Awards, Honors, & Recognition

Stimulating Access to Research in Residency (StARR) (R38HL155773) NIH, 2024
The Research Project Grant (R01CA272827) Co-PI NIH/NCI, 2022
Translational Research Award METAvivor, 2021
The Research Project Grant (R01CA255240) PI NCI, 2021
Investigator Initiated Translational Research Award DOD, 2019
Technology Impact Award Cancer Research Institute, 2019
STL Cure Sarcoma Research Award Sarcoma Foundation of America, 2017
Young Investigator Award Melanoma Research Alliance, 2015
Mentored Clinical Scientist Research Career Development Award (K08) NIH, 2015
Turcotte Enrichment Award Central Surgical Association Foundation, 2014
Faculty Research Fellowship Award American College of Surgeons, 2014
New Investigator Award Society of Thermal Medicine, 2010
Basic Research Award 1st place Western New York Chapter of the American College of Surgeons, 2009
Clinical Research Award 1st place Western New York Chapter of the American College of Surgeons, 2009
Travel Award Cancer and Leukemia Group B, 2008
Join now to see all

Clinical Trials

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Start of enrollment: 2023 Jan 09
Recruiting
Phase 1

Publications & Presentations

PubMed

27 citations
Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer
Fumito Ito, Amy W. Ku, Mark J. Bucsek, Jason B. Muhitch, Trupti Vardam-Kaur
Plos One. 2015-11-23
80 citations
Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s.
Takaaki Oba, Mark D. Long, Tibor Keler, Henry C. Marsh, Hans Minderman
Nature Communications. 2020-10-27
91 citations
Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines
Fumito Ito, Qiao Li, Andrew B. Shreiner, Ryuji Okuyama, Maria Jure-Kunkel
Cancer Research. 2004-11-15

Press Mentions

USC Team IDs Biomarker for NSCLC Response to ChemoimmunotherapyMay 17th, 2023
Study Identifies Biomarker That May Predict Treatment Response to ChemoimmunotherapyMay 12th, 2023
USC Research Identifies Biomarker That May Predict Treatment Response to ChemoimmunotherapyMay 12th, 2023
Join now to see all

Grant Support

Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy AssayNCI2022–2027
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors.National Cancer Institute (NCI)2021–2026
Translational Research AwardMETAvivor2022–2024
Technology Impact AwardCancer Research Institute2019–2021
Peripheral Blood T-cell Dynamic Biomarkers to Identify Responders and Nonresponders in Immune Checkpoint-based Therapy for Lung CancerDOD Lung Cancer Research Program for the Office of the Congressionally Directed Medical Research Programs (CDMRP)2019–2021
Blood-based T-cell Biomarkers for Prediction of Treatment Response and Early Diagnosis of Immune-related Adverse Events to Immune Checkpoint InhibitorsUniversity at Buffalo Clinical and Translational Science Institute (CTSI) Translational Pilot Studies Program2019–2020
Adoptive Cell Therapy with Rejuvenated Antigen-specific T cellsNational Cancer Institute (NCI)2015–2020
Pluripotent Stem Cell-derived Genome-edited Sarcoma-targeted T cells for ImmunotherapySarcoma Foundation of America2017–2018
Melanoma-Targeted T cells from Pluripotent Stem Cells for ImmunotherapyMelanoma Research Alliance2015–2018
Induced Pluripotent Stem Cells to Generate Patient- and Tumor-Specific T cells.American College of Surgeons2014–2016
Induced Pluripotent Stem Cells to Generate Patient- and Tumor-Specific T cellsCentral Surgical Association2013–2014

Committees

Leader, USC Translational and Clinical Sciences (TACS) program 2021 - Present
Member, Society for Immunotherapy of Cancer (SITC) Surgery Committee 2020 - 2022
Member, Biostatistics & Statistical Genomics Shared Resource Advisory Committee 2018 - 2021
Member, IRB 2016 - 2021
Member, RPCI-CCSG Tumor Immunology & Immunotherapy Program 2015 - 2021
Core member, University of Michigan Comprehensive Cancer Center 2011 - 2015
Member, Cancer Committee, Ann Arbor Veterans Affairs Hospital 2011 - 2015

Research History

Visiting ScholarCenter for iPS Research and Application, Kyoto University, Kyoto, Japan2011 - 2011
Clinical/Research FellowDepartment of Immunology, Roswell Park Cancer Institute2008 - 2010
Research FellowDivision of Surgical Oncology, Department of Surgery, University of Michigan2000 - 2003